Shandong Pharmaceutical Glass Co.Ltd

SHSE:600529 Stock Report

Market Cap: CN¥17.5b

Shandong Pharmaceutical GlassLtd Past Earnings Performance

Past criteria checks 5/6

Shandong Pharmaceutical GlassLtd has been growing earnings at an average annual rate of 12.3%, while the Medical Equipment industry saw earnings growing at 6.1% annually. Revenues have been growing at an average rate of 12.1% per year. Shandong Pharmaceutical GlassLtd's return on equity is 11.3%, and it has net margins of 17.2%.

Key information

12.3%

Earnings growth rate

9.6%

EPS growth rate

Medical Equipment Industry Growth16.0%
Revenue growth rate12.1%
Return on equity11.3%
Net Margin17.2%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

There Is A Reason Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Price Is Undemanding

Dec 13
There Is A Reason Shandong Pharmaceutical Glass Co.Ltd's (SHSE:600529) Price Is Undemanding

Returns On Capital At Shandong Pharmaceutical GlassLtd (SHSE:600529) Have Hit The Brakes

Aug 25
Returns On Capital At Shandong Pharmaceutical GlassLtd (SHSE:600529) Have Hit The Brakes

Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

May 31
Calculating The Fair Value Of Shandong Pharmaceutical Glass Co.Ltd (SHSE:600529)

The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

May 13
The Returns At Shandong Pharmaceutical GlassLtd (SHSE:600529) Aren't Growing

Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Apr 26
Shandong Pharmaceutical Glass Co.Ltd Just Recorded A 18% EPS Beat: Here's What Analysts Are Forecasting Next

Revenue & Expenses Breakdown

How Shandong Pharmaceutical GlassLtd makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SHSE:600529 Revenue, expenses and earnings (CNY Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 245,133882362160
30 Jun 245,146865370153
31 Mar 245,013830366147
31 Dec 234,982776344138
30 Sep 234,872738292128
30 Jun 234,633682285132
31 Mar 234,382632255136
31 Dec 224,187618264139
30 Sep 224,058616267138
30 Jun 224,040612255137
31 Mar 223,991588283133
31 Dec 213,875591241136
30 Sep 213,921620139137
30 Jun 213,703603165144
31 Mar 213,592585185143
31 Dec 203,427564241134
30 Sep 203,147532348121
30 Jun 203,093503366121
31 Mar 203,042484361127
31 Dec 192,992459364127
30 Sep 192,821437348127
30 Jun 192,720409352106
31 Mar 192,65138636890
31 Dec 182,58535833780
30 Sep 182,54632635377
30 Jun 182,481298304113
31 Mar 182,40028129791
31 Dec 172,33026330873
30 Sep 172,31425932454
30 Jun 172,2362363460
31 Mar 172,1812163300
31 Dec 162,0571903330
30 Sep 161,8601623060
30 Jun 161,8011592910
31 Mar 161,7581522860
31 Dec 151,7231452800
30 Sep 151,7711412700
30 Jun 151,7711302750
31 Mar 151,7171272520
31 Dec 141,6911252340
30 Sep 141,6531172250
30 Jun 141,5991222160
31 Mar 141,5771212100
31 Dec 131,5451222090

Quality Earnings: 600529 has high quality earnings.

Growing Profit Margin: 600529's current net profit margins (17.2%) are higher than last year (15.1%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 600529's earnings have grown by 12.3% per year over the past 5 years.

Accelerating Growth: 600529's earnings growth over the past year (19.6%) exceeds its 5-year average (12.3% per year).

Earnings vs Industry: 600529 earnings growth over the past year (19.6%) exceeded the Medical Equipment industry -8.8%.


Return on Equity

High ROE: 600529's Return on Equity (11.3%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/24 11:51
End of Day Share Price 2024/12/24 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Shandong Pharmaceutical Glass Co.Ltd is covered by 21 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yin ZhangBOCI Research Ltd.
Chao FanChangjiang Securities Co. LTD.
Liang LongChasing Securities